P Nayak, V Bentivoglio, M Varani, A Signore - Cancers, 2023 - mdpi.com
Simple Summary Cancer is a global public health issue. The development and use of in vitro cellular models with pre-clinical animal models are essential to elucidate the complex …
DB Rein, JS Wittenborn, X Zhang… - Archives of …, 2009 - jamanetwork.com
Objective To forecast age-related macular degeneration (AMD) and its consequences in the United States through the year 2050 with different treatment scenarios. Methods We …
MM Brown, GC Brown, S Sharma, J Landy - Survey of ophthalmology, 2003 - Elsevier
Health care economic analyses are becoming increasingly important in the evaluation of health care interventions, including many within ophthalmology. Encompassed with the …
PURPOSE: To test the assumption that the National Eye Institute Visual Function Questionnaire (NEI VFQ) measures visual functioning, assess the validity of its subscales …
M Drummond, M Sculpher - Medical care, 2005 - journals.lww.com
Economic evaluations are increasingly being used by those bodies such as government agencies and managed care groups that make decisions about the reimbursement of health …
PURPOSE: To examine combined photodynamic therapy (PDT) with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization (CNV) secondary to …
J Raftery, A Clegg, J Jones, SC Tan… - British Journal of …, 2007 - bjo.bmj.com
Two new drugs provide startling benefits in the treatment of age-related macular degeneration (AMD). The clinical and cost effectiveness of ranibizumab (Lucentis) was …
JS Slakter, M Stur - Survey of ophthalmology, 2005 - Elsevier
Age-related macular degeneration (AMD) is a chronic, progressive, degenerative disease of the macula and is the leading cause of central vision loss among elderly people in the …
MM Brown, GC Brown, S Sharma, B Busbee - Ophthalmology, 2003 - Elsevier
PURPOSE: To assess the visual utility values of patients with ocular disease and to compare these values with those of patients with systemic health states DESIGN: Cross-sectional …